IMMUNO-ONCOLOGY PLATFORM

and Emerging Targets in Oncology

Chapters

Current Treatment Landscape for Cancer

BiTE^® Immuno-Oncology Platform

Investigational Targets with the BiTE^® Platform in Hematologic Malignancies: Multiple Myeloma and B-Cell Maturation Antigen (BCMA)

Investigational Targets with the BiTE^® Platform in Solid Malignancies: Prostate Cancer and Prostate-Specific Membrane Antigen (PSMA)

Additional Emerging Targets for Investigation With the BiTE^® Immuno-Oncology Platform

Ajai Chari, MD

Mount Sinai School of Medicine

The design of the BiTE^® technology¹

The potential of the BiTE^® platform to target a range of tumors²

The major milestones in cancer treatment^3,4

The cancer treatment landscape and how it has evolved with immuno-oncology therapies⁵

References

Yuraszeck T, Kasichayanula S, Benjamin JE. Translation and clinical development of bispecific T-cell engaging antibodies for cancer treatment. Clin Pharmacol Ther. 2017;101(5):634-645.
Amgen pipeline. Amgen website. https://www.amgenpipeline.com/-/media/themes/amgen/amgenpipeline-com/amgenpipeline-com/pdf/amgen-pipeline-chart.pdf. Accessed October 17, 2019.
Cancer progress timeline. ASCO website. https://www.asco.org/research-guidelines/cancer-progress-timeline. Accessed October 17, 2019.
Timeline of progress in immunotherapy. CRI website. www.cancerresearch.org/immunotherapy/timeline-of-progress. Accessed October 17, 2019.
Hoos A, Britten C. The immuno-oncology framework: Enabling a new era of cancer therapy. Oncoimmunology. 2012;1(3):334-339.

Dr. Chari did not accept an honorarium for this program.

Amgenoncology.com